| アブストラクト | BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy offers a promising and transformative treatment option for patients with hematologic malignancies, with expanding potential in solid tumors and non-malignant diseases. However, it also exposes recipients to a wide spectrum of treatment-related toxicities, complicating its clinical implementation. The limited sample sizes of clinical studies hinder a comprehensive understanding of how different adverse events (AEs) may impact CAR-T treatment outcomes. METHODS: Based on two global real-world drug safety surveillance systems, this observational pharmacovigilance study identified safety signals and death-related AEs in CAR-T cell therapy. All consecutive CAR-T cell-treated cases with AEs reported to the World Health Organization' VigiBase (as of March 2025) and U.S. Food and Drug Administration Adverse Event Reporting System (as of June 2024) were included. We evaluated disproportionate risk and death of all reported AEs by the modified reporting odds ratio method. AE fatality rates, reporting odds ratio of fatality rates among different AEs, and CAR-T cell therapy safety signals were reported. FINDINGS: This analysis included 12,511 CAR-T cell-treated cases in FAERS from 37 countries/regions, 2861 had a fatal outcome. Disproportionality analysis identified 266 AEs as safety signals associated with CAR-T therapy. Of these, 59 high-fatality AEs were revealed (average fatality rate 49.35% [189/383]), such as pulmonary hemorrhage, lactic acidosis, and hemophagocytic lymphohistiocytosis. Cardiac events and respiratory/infection-related complications showed notably high fatality and high reporting frequencies, respectively. We identified 31 low-fatality AEs indicating a comparatively better outcome (average fatality: 11.47% [710/6188]), such as cytokine release syndrome, bradyphrenia, and hypocalcemia, which were predominantly neurologic or immune-related. These prognostically significant AEs were also borne out as death signals for CAR-T cell administration in 5555 CAR-T cell-treated cases from VigiBase. INTERPRETATION: This work establishes a systematic mapping of prognostically significant AEs in CAR-T cell therapy, providing a data-driven resource to inform future research and toxicity management strategies. Given the inherent limitations in pharmacovigilance data, including potential reporting bias and temporal ambiguities, the identified signals require further research to validate causality. FUNDING: This study was funded by the National Key Research and Development Program of China (2022YFC2804300), the National Natural Science Foundation of China (82222047, W2411079), the Science and Technology Commission of Shanghai Municipality (22XD1423100), and the Shanghai Municipal Health Commission (2022XD057, 2024ZZ1008). |
|---|
| ジャーナル名 | EClinicalMedicine |
|---|
| Pubmed追加日 | 2026/1/7 |
|---|
| 投稿者 | Sun, Zhen; Guo, Jianglong; Liu, Mengsi; Wang, Hongye; Li, Zhe; Shen, Weiming; Wang, Siying; Zhu, Huijue; Liu, Xiaoye; Li, Jinhao; Ouyang, Yuan; Zhu, Yueze; Ye, Zhen; Xing, Shunpeng; Chen, Gang; Jin, Haojie |
|---|
| 組織名 | State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute,;Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,;China.;Guangdong Cardiovascular Institute, Guangzhou, China.;Department of Biliary and Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong;University School of Medicine, Shanghai, China.;Hengyang Medical School, University of South China, Hengyang, China.;The First Affiliated Hospital of University of South China, Hengyang, China.;Department of Critical Care Medicine, Renji Hospital, Shanghai Jiao Tong;Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery & Translation,;Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of;Wenzhou Medical University, Wenzhou, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41497502/ |
|---|
